Research News and Research

RSS

GE Healthcare joins TRIL Centre as second industry partner

The TRIL (Technology Research for Independent Living) Centre, Ireland is delighted to announce a new industry partner, GE Healthcare. TRIL is a groundbreaking research initiative, founded in January 2007 by Intel Corporation and the IDA Ireland (Industrial Development Agency), to explore the physical, cognitive and social consequences of ageing and design technologies to help address them. The addition of GE Healthcare as an industry partner will help TRIL to extend and expand its research programme.

28 Apr 2010

FXR can slow proliferation of tamoxifen-resistant breast cancer cells: Study

A receptor that is present in the nucleus of cells can, when activated, slow the growth of tamoxifen-resistant breast cancer cells, a new study found. The study built on the recent discovery that farnesoid X receptor — a nuclear receptor found mainly in the liver — is found in breast cancer tissue.

28 Apr 2010

Study finds kids five and younger dangerously physically inactive

According to the 2010 Active Healthy Kids Canada Report Card on Physical Activity for Children and Youth, Canadian kids five and younger are dangerously physically inactive. Healthy habits must start young, as lifestyle patterns set in the early years predict obesity and health outcomes in later childhood, and even through adulthood.

28 Apr 2010

AAP testimony asks CDC DOH to include periodontal surveillance as part of strategic priorities

The American Academy of Periodontology was recently invited to provide testimony to the Centers for Disease Control and Prevention's Division of Oral Health as part of the strategic planning process for 2011 through 2014.

28 Apr 2010

High dose B-vitamin therapy slows progression of diabetic nephropathy: Study

Patients with diabetic nephropathy (kidney disease caused by diabetes) who received high dose B-vitamin therapy experienced a more rapid decline in kidney function and had a higher rate of heart attack and stroke than patients who received placebo, according to a study in the April 28 issue of JAMA.

28 Apr 2010

Kaiser Permanente approves over 250 grants and donations totaling $7 million

Kaiser Permanente, one of America's leading health care providers and nonprofit health plans, announced today it approved more than 250 grants and donations nationwide totaling approximately $7 million in the first quarter of 2010. The grants focused on expanding access to nutritious food, providing safe spaces for all ages to increase physical activity, increasing opportunities for continuing education, and eliminating health disparities.

28 Apr 2010

Cancer-related expenditures increase faster than any other area of health care: JAMA

From 1999 through 2006 the use of diagnostic imaging for Medicare patients with cancer increased, with use of positron emission tomography increasing the most significantly, according to a study in the April 28 issue of JAMA. Imaging costs for these patients also increased, outpacing the rate of increase in total costs among Medicare beneficiaries with cancer.

28 Apr 2010

CTI receives positive reception from EMEA clinical experts for pixantrone MAA

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the first quarter ended March 31, 2010.

28 Apr 2010

Potential new treatment for osteonecrosis

Researchers at Mount Sinai School of Medicine have found a potential new treatment for osteonecrosis, or the death of bone tissue, in people who are treated with steroids for several common medical conditions. There are currently no treatment options for people with this debilitating disease. The research is published in the April 27 issue of Proceedings of the National Academy of Sciences.

28 Apr 2010

IMB awards manufacturer licenses to PPD’s Athlone facility

PPD, Inc. today announced its contract research facility in Athlone, Ireland, has been awarded manufacturer licenses by the Irish Medicines Board. The licenses support investigational medicinal products and marketed products and provide laboratory certifications for quality control of medicinal products.

28 Apr 2010

Causes of death in AIDS patients

New research shows that Antiretroviral Therapy (ART) continues to dramatically reduce rates of mortality from HIV infection in high-income countries, such that non-AIDS-related deaths exceed AIDS deaths after approximately four years of taking ART.

28 Apr 2010

Pepscan reaches partnering agreement for therapeutic vaccine portfolio with Immunovo

Pepscan, the Netherlands based biotechnology firm focusing on protein mimicking technology for the generation of immune therapeutics, today announced that it reached a partnering agreement for its therapeutic vaccine portfolio with Immunovo BV of 's-Hertogenbosch. Under the terms of the agreement Pepscan will receive an undisclosed cash payment as well as a minority interest in Immunovo.

28 Apr 2010

Researchers participate in national multi-center trial comparing treatments for diabetic macular edema

A drug may be more effective against the leading cause of adult blindness than laser treatments, a new study has shown.

28 Apr 2010

State Round-up: Federal prosecutors investigate bid rigging at New York hospitals; Montana prepares for health reform implementation; and Florida spares Medicaid from budget cuts

The Wall Street Journal: "Federal prosecutors are investigating allegations that bid rigging and fraud at Mount Sinai Medical Center and New York-Presbyterian Hospital resulted in the hospitals awarding contracts worth tens of millions of dollars to outside contractors. Purchasing officials at the hospitals ... are alleged to have gotten more than a million dollars in payments from companies that were then given lucrative contracts to perform work such as re-insulating pipes and removing asbestos, according to documents filed in the Southern District of New York.

28 Apr 2010

Coronary artery calcium score helpful for determining intermediate risk of heart disease

Including a coronary artery calcium score in a risk assessment for future heart disease events, such as heart attacks, provides a better estimate in some populations than a standard coronary risk factors assessment, according to research supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.

28 Apr 2010

Seattle Genetics reports revenues of $46.5M for first-quarter 2010

Seattle Genetics, Inc. today reported financial results for the first quarter ended March 31, 2010. The company also highlighted recent product development activities and planned milestones.

28 Apr 2010

Researchers develop new diagnostic approach to fight against Chagas disease

Chagas disease is one of the most deadly parasitic diseases in the world. It affects more than 10 million people, primarily in the Americas. In South America alone it kills 50 000 people each year. A reliable and rapid diagnosis is the key in the battle against infection but until now, this has been next to impossible.

28 Apr 2010

Trade negotiations between EU, India could affect access to low-cost generics

The Associated Press examines the ongoing free-trade negotiations between the EU and India - a country that according to PricewaterhouseCoopers currently "makes one-fifth of the world's generics." The negotiations "could make it harder for millions … across the developing world to get lifesaving drugs. The deal is taking shape as India tries to transform itself from a generics powerhouse into a base for drug discovery - a trend that could ultimately do more than any trade agreement to curtail its reign as a pharmacy to the poor."

28 Apr 2010

Study: Lower blood oxygen levels can lead to heart abnormalities in children with sickle cell disease

Children with sickle cell disease who also have lower blood oxygen levels while both asleep and awake are likely to have heart abnormalities, researchers at Washington University School of Medicine in St. Louis and other institutions have found.

28 Apr 2010